FoundationOne provides in-home blood collections for patients.
Order this test only if in-home collection is not an option for the patient.
Blood tumor mutational burden (bTMB), microsatellite instability (MSI),† and tumor fraction values.
Collection tubes included in the FoundationOne CDx kit
Specimen collection should be scheduled in advance in order to obtain the specialty kit for collection from the Central supply area. Only collect specimens Mo – Th.
Draw patient using blood tubes supplied in the FoundationOne kit
Collection tubes from the FoundationOne CDx collection kit
Ambient (strict) - 7 days
Refrigerated – NO
Frozen – NO
FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions,insertions and deletions (indels) in 311 genes, rearrangements in four (4) genes, and copy number alterations in three (3) genes. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne Liquid CDx cfDNA blood collection tubes included in the FoundationOne Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies.
See report
Includes guideline-recommended genes and biomarkers to help guide therapy selection and identify clinical trial options for patients with solid tumors.
Cancer type: Solid Tumors